Displaying drugs 7376 - 7400 of 8025 in total
Vafidemstat
Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).
Investigational
Matched Description: … Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of …
TAK-611
TAK-611, formerly known as SHP611, is a recombinant human arylsulfatase A. First developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy.
Investigational
Matched Description: … First developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy …
KP1237
KP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal antibody binding terminus binder) connected by a linker chain.
Investigational
Matched Description: … KP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal …
Alvocidib
Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.
Experimental
Investigational
Matched Description: … Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of …
Iratumumab
Immunoglobulin G1, anti-(human CD30 (antigen)) (human monoclonal MDX-060 heavy chain), disulfide with human monoclonal MDX-060 light chain, dimer. Molecular weight is approximately 170,000 daltons. In phase I/II clinical trials for treatment of CD30+ lymphomas.
Investigational
Matched Description: … In phase I/II clinical trials for treatment of CD30+ lymphomas. …
Ulimorelin
Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility of the GI tract is severely impaired.
Investigational
Matched Description: … first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility of …
FT-1101
FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies).
Investigational
Matched Description: … [A257301] FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor …
SUVN-502
SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer’s and Schizophrenia, an unmet medical need.
Investigational
Matched Description: … active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of …
Lexacalcitol
Lexacalcitol is a solid. This compound belongs to the vitamin D and derivatives class of chemicals. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane. It is known to target the vitamin D3 receptor.
Experimental
Matched Description: … This compound belongs to the vitamin D and derivatives class of chemicals. …
Apadenoson
Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. It is developed by Bristol-Myers Squibb and is in phase II of clinical trials.
Investigational
Matched Description: … It is developed by Bristol-Myers Squibb and is in phase II of clinical trials. …
EP-2104R
EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly. It is being developed by EPIX Pharmaceuticals, Inc.
Investigational
Matched Description: … EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. …
ISIS 14803
ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell culture.
Investigational
Matched Description: … oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of …
Tiletamine
This drug is a dissociative anesthetic agent that falls under the drug category of NMDA receptor antagonists. Tiletamine is chemically similar to another dissociative anesthetic, ketamine. Tiletamine hydrochloride, the salt form, exists as odorless white crystals.
Vet approved
Matched Description: … This drug is a dissociative anesthetic agent that falls under the drug category of _NMDA receptor antagonists …
Garadacimab
Garadacimab is under investigation in clinical trial NCT04281524 (A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line).
Investigational
Matched Description: … under investigation in clinical trial NCT04281524 (A Clinical Study to Test the Efficacy and Safety of …
Edodekin alfa
Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery).
Investigational
Matched Description: … NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of …
Vonlerolizumab
Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy).
Investigational
Matched Description: … Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination …
AGS-16C3F
AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate. AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma).
Investigational
Matched Description: … AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. …
NBI-6024
NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.
Investigational
Matched Description: … an altered peptide ligand that is designed to cause an immune response which result in preservation of …
CPD 923
CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
Investigational
Matched Description: … CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. …
Ethyl biscoumacetate
Ethyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)
Withdrawn
Matched Description: … It has actions similar to those of Warfarin. …
Cythioate
Cythioate is a member of the organothiophosphate compounds that is used as an insecticide and anthelmintic. It is mainly used in veterinary as a treatment for fleas.
Vet approved
Matched Description: … Cythioate is a member of the organothiophosphate compounds that is used as an insecticide and anthelmintic …
Emibetuzumab
Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
Investigational
Matched Description: … Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, …
Lumretuzumab
Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
Investigational
Matched Description: … Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small …
Milatuzumab
Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
Investigational
Matched Description: … Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), …
Rovalpituzumab tesirine
Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
Investigational
Matched Description: … Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma …
Displaying drugs 7376 - 7400 of 8025 in total